• About
  • Submit Article/PR
  • Contact
Friday, March 24, 2023
No Result
View All Result
  • Login
The Healthcare Daily
WHO COVID DASHBOARD
  • Home
  • News
    • All
    • Biotech
    • By Speciality
    • Generic Drugs
    • Insurance
    • Investment
    • Medical Tourism
    • Pharma
    What-Chronic-Disease-Management-Is-All-About-How-to-Deal-with-It-Healthcare-Daily

    What Chronic Disease Management Is All About & How to Deal with It

    cancer-cure-TheHealthcareDaily

    Cancer Cure: Is there a cure for it?

    Womens-Reproductive-Rights-Around-the-world-Healthcare-Daily

    Women’s Reproductive Rights Around the World : Rights 101

    Everything-about-Telehealth-reimbursement-and-insurance-coverage-Healthcare-Daily

    Absolutely Everything about Telehealth Reimbursement and Coverage : Healthcare 101

    Everything-about-Personalized-Medicine-in-2023-Healthcare-Daily

    Everything about Personalized Medicine in 2023

    Healthcare cost containment and insurance reform

    Healthcare cost containment and insurance reform

    Understanding Chronic Diseases: Symptoms, Causes, and Treatment Options

    The Most Common Dental Mistakes in Healthcare Industry

    The 6 Most Common Dental Mistakes in Healthcare Industry

    How To Get a Dental Checkup for Free (or Cheap)

    How To Get a Dental Checkup for Free (or Cheap)

  • Insights
    • All
    • Analysis
    • Interview
    • Opinion
    • Reports
    Workforce-Diversity-and-its-5-Benefits-in-healthcare-Daily

    Workforce Diversity and it’s 5 Benefits in healthcare

    Healthcare-Affordability-in-United-States-Healthcare-101-Daily

    Healthcare Affordability in United States : Healthcare 101

    The-Benefits-and-Challenges-of-Data-and-Analytics-in-Healthcare-Daily

    The Benefits and Challenges of Data and Analytics in Healthcare

    Healthcare-Industry-At-A-Glance-Healthcare-DAily

    Healthcare Industry At A Glance

    7-Reasons-Millennials-Are-The-Most-Disruptive-Generation-Yet-Healthcare-Daily

    7 Reasons Millennials Are The Most Disruptive Generation Yet

    Technological-challenges-faced-by-pharma-companies-today-Healthcare-Daily

    Technological challenges faced by Pharma Companies Today

    Senior living options in Canada

    Senior living options in Canada in 2022

    A Guide to Medical Tourism in India: Everything You Need to Know

    A Guide to Medical Tourism in India: Everything You Need to Know

    5 Things to know before adopting a child

    Adoption: 5 Things to know before going for a successful child adoption

  • HealthTech
    • All
    • Hardware
    • Innovation
    • Software
    Overview-of-healthcare-hackathons-and-competitions-focused-on-healthcare-innovation-thehealthcaredaily

    Overview of healthcare hackathons and competitions focused on healthcare innovation

    Everything-about-Telehealth-reimbursement-and-insurance-coverage-Healthcare-Daily

    Absolutely Everything about Telehealth Reimbursement and Coverage : Healthcare 101

    Everything-about-Personalized-Medicine-in-2023-Healthcare-Daily

    Everything about Personalized Medicine in 2023

    5-Amazing-Advancements-in-Medical-Technology-2023-Healthcare-Daily

    5 Amazing Advancements in Medical Technology 2023

    Pros-and-Cons-of-Telemedicine-Healthcare-Daily

    Pros and Cons of Telemedicine in Healthcare 2023

    The-Benefits-and-Challenges-of-Data-and-Analytics-in-Healthcare-Daily

    The Benefits and Challenges of Data and Analytics in Healthcare

    Healthcare workforce and talent management

    Healthcare workforce and talent management

    Healthcare cost containment and insurance reform

    Healthcare cost containment and insurance reform

    Telehealth and digital health solutions

    Telehealth and digital health solutions

  • Pharma
  • Events
  • NewsMakers
  • World
  • Home
  • News
    • All
    • Biotech
    • By Speciality
    • Generic Drugs
    • Insurance
    • Investment
    • Medical Tourism
    • Pharma
    What-Chronic-Disease-Management-Is-All-About-How-to-Deal-with-It-Healthcare-Daily

    What Chronic Disease Management Is All About & How to Deal with It

    cancer-cure-TheHealthcareDaily

    Cancer Cure: Is there a cure for it?

    Womens-Reproductive-Rights-Around-the-world-Healthcare-Daily

    Women’s Reproductive Rights Around the World : Rights 101

    Everything-about-Telehealth-reimbursement-and-insurance-coverage-Healthcare-Daily

    Absolutely Everything about Telehealth Reimbursement and Coverage : Healthcare 101

    Everything-about-Personalized-Medicine-in-2023-Healthcare-Daily

    Everything about Personalized Medicine in 2023

    Healthcare cost containment and insurance reform

    Healthcare cost containment and insurance reform

    Understanding Chronic Diseases: Symptoms, Causes, and Treatment Options

    The Most Common Dental Mistakes in Healthcare Industry

    The 6 Most Common Dental Mistakes in Healthcare Industry

    How To Get a Dental Checkup for Free (or Cheap)

    How To Get a Dental Checkup for Free (or Cheap)

  • Insights
    • All
    • Analysis
    • Interview
    • Opinion
    • Reports
    Workforce-Diversity-and-its-5-Benefits-in-healthcare-Daily

    Workforce Diversity and it’s 5 Benefits in healthcare

    Healthcare-Affordability-in-United-States-Healthcare-101-Daily

    Healthcare Affordability in United States : Healthcare 101

    The-Benefits-and-Challenges-of-Data-and-Analytics-in-Healthcare-Daily

    The Benefits and Challenges of Data and Analytics in Healthcare

    Healthcare-Industry-At-A-Glance-Healthcare-DAily

    Healthcare Industry At A Glance

    7-Reasons-Millennials-Are-The-Most-Disruptive-Generation-Yet-Healthcare-Daily

    7 Reasons Millennials Are The Most Disruptive Generation Yet

    Technological-challenges-faced-by-pharma-companies-today-Healthcare-Daily

    Technological challenges faced by Pharma Companies Today

    Senior living options in Canada

    Senior living options in Canada in 2022

    A Guide to Medical Tourism in India: Everything You Need to Know

    A Guide to Medical Tourism in India: Everything You Need to Know

    5 Things to know before adopting a child

    Adoption: 5 Things to know before going for a successful child adoption

  • HealthTech
    • All
    • Hardware
    • Innovation
    • Software
    Overview-of-healthcare-hackathons-and-competitions-focused-on-healthcare-innovation-thehealthcaredaily

    Overview of healthcare hackathons and competitions focused on healthcare innovation

    Everything-about-Telehealth-reimbursement-and-insurance-coverage-Healthcare-Daily

    Absolutely Everything about Telehealth Reimbursement and Coverage : Healthcare 101

    Everything-about-Personalized-Medicine-in-2023-Healthcare-Daily

    Everything about Personalized Medicine in 2023

    5-Amazing-Advancements-in-Medical-Technology-2023-Healthcare-Daily

    5 Amazing Advancements in Medical Technology 2023

    Pros-and-Cons-of-Telemedicine-Healthcare-Daily

    Pros and Cons of Telemedicine in Healthcare 2023

    The-Benefits-and-Challenges-of-Data-and-Analytics-in-Healthcare-Daily

    The Benefits and Challenges of Data and Analytics in Healthcare

    Healthcare workforce and talent management

    Healthcare workforce and talent management

    Healthcare cost containment and insurance reform

    Healthcare cost containment and insurance reform

    Telehealth and digital health solutions

    Telehealth and digital health solutions

  • Pharma
  • Events
  • NewsMakers
  • World
No Result
View All Result
The Healthcare Daily
No Result
View All Result

Drug Amylyx: FDA advisors support Drug Amylyx for ALS, altering previous stance

by THD Desk
September 14, 2022
in Featured, Health, Testing
Reading Time: 5 mins read
0
Drug-amylyx gets supported

Source: Google Images

0
SHARES
Share on FacebookShare on Twitter

A group of Food and Drug Administration advisers has recently come out in favour of a carefully monitored ALS drug, increasing the likelihood that the agency will approve it in the coming weeks.

The expert group voted 7-2 in favour of the medicine AMX0035 on Wednesday, deciding that the evidence gathered so far is sufficient to support its approval for sale in the United States. At a previous meeting at the end of March, the same panel of experts had barely voted against the drug.

Although it is not mandatory, the FDA frequently abides by the advice of its advisors. By September 29th, the agency hopes to have a decision on AMX0035. ALS, or amyotrophic lateral sclerosis, is a rare, frequently rapidly progressing disease that kills nerve cells and is typically fatal within two to five years of diagnosis. If approved, it would join a small list of treatments for ALS.

According to Avindra Nath, clinical director of the National Institute of Neurological Disorders and Stroke and committee member, “last time I was on the fence and wasn’t really sure which way to go.” This time, the conversation assisted me in moving a little bit closer to saying yes.

In addition to over two dozen other physicians, advocates, and patients who testified during the meeting’s open public hearing, two renowned ALS researchers who appeared on behalf of Amylyx Pharmaceuticals, the drug’s Massachusetts-based developer, endorsed the case for AMX0035.

Merit Cudkowicz, director of the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital, stated on Wednesday that “AMX0035 needs to be something we can offer our patients today.”

In the primary clinical trial that Amylyx is utilising to secure an approval, Cudkowicz was one of the key researchers. Patients who took Amylyx’s medication lived slightly longer and decreased more slowly than those who received a placebo, according to study findings, some of which were published in The New England Journal of Medicine.

two committee participants, G. AMX0035 was defeated by Caleb Alexander from the Johns Hopkins Bloomberg School of Public Health and Kenneth Fischbeck from the National Institutes of Health.

Drug-amylyx gets supported

Although promising, in combination with the earlier evidence, I regrettably do not think the new evidence we’ve evaluated represents sufficient proof of effectiveness. We essentially have one paper that raises a lot of important, non-trivial scientific issues.

ALS patients and support organisations have repeatedly pushed the FDA to approve AMX0035 because there are few other therapy options. However, agency personnel have criticised the information Amylyx gathered and the company’s methods of analysis.

Even though Amylyx’s trial achieved its primary objective, which is unusual in the development of ALS drugs, they previously deemed the findings to be “not extraordinarily persuasive.” However, they are aware of how devastating ALS is and the need for further treatment alternatives.

Billy Dunn, director of the Office of Neuroscience in the FDA division that assesses new medications, said, “We are particularly sensitive to the urgent need for the development of novel medicines for ALS.” 

Early in the discussion on Wednesday, Dunn spoke extensively and at one point pressured the co-founders of Amylyx to state they would voluntarily pull AMX0035 off the market if a larger, ongoing trial intended to confirm its usefulness failed. One of the company’s founders, Justin Klee, concurred that it would.

The vote in favour Wednesday indicates that although it is still uncertain, approval is more likely than it was earlier this year. 

The FDA advisory committee’s opinion of AMX0035 was split nearly evenly in March. The primary clinical research revealed that those taking the medication were able to better maintain necessary bodily processes like breathing, eating, and moving. Additionally, they lived 4.8 months longer on average than those in the placebo group. However, the then-group of 10 advisers voted against approval by a margin of 6 to 4.

Since then, Amylyx has gathered further information and performed post-mortem investigations that, in its opinion, add to the body of evidence showing how effective their medication is for patients. These new data prompted the FDA to take the highly unusual step of reconvening its advisers to further discuss AMX0035. For example, the company claims that the survival benefit rises to approximately 10 months when accounting for patients who started on a placebo but then switched to AMX0035 in a subsequent “open-label extension study.”

However, prior to the hearing on Wednesday, FDA personnel seemed to be doubtful of Amylyx’s interpretation of the results, stating that the new survival analyses cannot be viewed as independent confirmatory evidence. However, they also gave advisors instructions to take ALS’s characteristics and the dearth of efficient treatments into account.

The FDA stated in briefing documents published earlier this week that “in the neurological arena, we will dependably assess the evidence, whatever its magnitude, in that context.”

The FDA’s historical adaptability with regards to prospective treatments for illnesses of the nerve and brain system was also acknowledged by agency officials. Based on findings from a single study that some medical professionals claim aren’t as compelling as those obtained with AMX0035, a medicine by the name of Radicava was approved for use as an ALS treatment in 2017. Then, in 2017, the FDA granted Aduhelm, a contentious Alzheimer’s disease drug with a rocky testing history, a first-of-its-kind approval.

The FDA’s stance during the meeting on Wednesday irritated Mark Weston, the authorised patient representative. Why did Amylyx have to go through this again at the FDA’s request? ” Did he ask? “I am aware that neither of you have decided. I am aware that it is not yet finished. But there’s not a lot of favourable conversation about the outcomes of this new analysis.”

Director of the FDA section that specially evaluates medications like AMX0035, Teresa Burrachio, responded, “I can promise you that this isn’t just something to go through the motions.” We acknowledge the studies’ shortcomings, but we haven’t ruled out the possibility that they could serve as confirming evidence, which is why we’re in this place right now.

Bryan Traynor, a senior researcher at the Senior National Institute for Aging, and Weston were two of the seven people who voted in support of AMX0035. According to Traynor, his vote “first and foremost” reflected the urgent need for new ALS medicines. However, it was also persuaded by Amylyx’s promise to withdraw its medication if confirmatory testing fails, as well as remarks from the FDA, which claimed to have procedures in place to take AMX0035 off the market.

Alexander, on the other hand, wasn’t as enthused about the market withdrawal backstop.

With all due respect, he claimed that “the FDA dramatically understates the complexity and likelihood of them removing a product from the market.” “Honestly, I don’t think it’s ever happened,”

More than half of the 600 participants who were intended to join in PHOENIX, Amylyx’s confirmatory study, have already done so. In 2024, results are anticipated. 

 

THD Desk

THD Desk

Next Post
Survey on university cost

Survey: University costs in England and wales are " poor value for money"

Recommended

Delhi Govt to create surveillance site for testing vaccines

Delhi Govt to create surveillance site for testing vaccines

2 years ago
Everything-about-Telehealth-reimbursement-and-insurance-coverage-Healthcare-Daily

Absolutely Everything about Telehealth Reimbursement and Coverage : Healthcare 101

1 month ago

About Us

A daily dose of news, views, opinions, and actionable information from the global healthcare industry. Our newsletter is available for a limited audience. If you are interested to write or contribute to this portal then please get in touch.

Contact Us

Medianiti Ltd, Brooklands Business Park, Wellington Way, Weybridge KT13 0TT,
United Kingdom
General: hello@thehealthcaredaily.com

Important Links

  • Home
  • World
  • Business
  • Health

Recent News

Overview of healthcare hackathons and competitions focused on healthcare innovation

Exclusive interviews with healthcare thought leaders and executives

  • About
  • Submit Article/PR
  • Contact

© 2020 THP - A Medianiti Venture.

No Result
View All Result
  • Home
  • World
  • Business
  • Health

© 2020 THP - A Medianiti Venture.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In